December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Niagen Bioscience, Inc. - Common Stock (NQ:NAGE)

3.265 -0.055 (-1.66%)
Streaming Delayed Price Updated: 12:41 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Niagen Bioscience, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience (NASDAQ:NAGE) Shares Slide After Q1 Earnings Miss and Spending Guidance ↗
Via Chartmill
Topics Earnings
Niagen Bioscience Inc (NASDAQ:NAGE) Reports Q4 2025 Revenue Beat and Mixed Earnings ↗
Via Chartmill
News headline image
Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
From Niagen Bioscience, Inc.
Via Business Wire
News headline image
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen (NAGE) Q1 2026 Earnings Call Transcript ↗
Niagen (NAGE) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas
From Niagen Bioscience, Inc
Via Business Wire
Four Stocks at the Intersection of Enzymes, Longevity, and the $400 Billion Wellness Boom (CELV, NAGE, MTEX, CDXS)
Via AB Newswire
News headline image
Niagen Bioscience Increases Share Repurchase Program to $20 Million
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Present at the 38th Annual ROTH Conference
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience (NAGE) Earnings Transcript ↗
Niagen Bioscience (NAGE) Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
News headline image
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®
From Niagen Bioscience, Inc
Via Business Wire
Get insights into the top gainers and losers of Wednesday's after-hours session. ↗
Via Chartmill
News headline image
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®
From Niagen Bioscience, Inc
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.